Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

7.390 +0.010 (+0.14%)
Official Closing Price Updated: 7:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,340,919
Open 7.510
Bid (Size) 7.400 (10)
Ask (Size) 7.470 (25)
Prev. Close 7.380
Today's Range 7.370 - 7.645
52wk Range 6.779 - 11.45
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Teva Concludes Nationwide Opioids Settlement Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire

Performance

YTD
-22.46%
-22.46%
1 Month
-18.43%
-18.43%
3 Month
-23.42%
-23.42%
6 Month
-12.54%
-12.54%
1 Year
-17.25%
-17.25%

More News

Read More
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
From Phil Inc.
Via Business Wire
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
Via The Motley Fool
Why Teva Pharmaceutical Stock Is Jumping Today
Via The Motley Fool
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales
Via Investor's Business Daily
Teva Pharmaceutical Clocks Lower Profits On Flat Q1 Sales, Sticks To Annual Guidance
Via Benzinga
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Teva Pharmaceutical Indus: Q1 Earnings Insights
Via Benzinga
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Via InvestorPlace
Why Is Teva Pharmaceuticals (TEVA) Stock Up Today?
Via InvestorPlace
Netflix, Synopsys, Madison Square Garden Entertainment And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Teva Launches New “Pivot to Growth” Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
Via Benzinga
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
Via Benzinga
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
Nasdaq, S&P 500 Futures Slip Ahead Of Inflation Data — But Analyst Hints It Still Might Be Ok To Be Bullish
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.